Clinical Study
Volixibat: A Possible Rare Liver Disease Medication
PBC is a chronic rare liver disease. Volixibat is a potential medication for symptoms of this disease. Scientists and doctors do not know the safety and effectiveness of this drug. Research is needed to learn if it may be approved by the United States Food and Drug Administration (FDA) and then used to improve the health of PBC patients.
For more information contact:
Srinivas Mulamalla
srinivas.mulamalla@hsc.utah.edu
801-585-2283
IRB#: IRB_00148152
| PI: Juan Gallegos-Orozco
| Department: GASTROENTEROLOGY
| Approval Date: 2022-05-25 06:00:00
Specialties: Gastroenterology
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Will I be paid for my time?
Yes